Patients affected by chronic kidney disease (CKD) suffer by secondary hyperparathyroidism and hyperphosphatemia. The new KDIGO guidelines identify a new definition in CKDMBD (Mineral Bone Disorder), in which vascular calcification plays a central role. In fact, CKD patients that present vascular calcification have highest risk of cardiovascular morbility and mortality. Recently, it has been elucidated that the control of phosphate is one of the major problems for the nephrology community. Furthermore, new markers, such as FGF- 3, have been identified as inducers of vascular calcification and cardiovascular disease in CKD. Therefore, the use of calcium-free phosphate-bindersmay reduce the risk of cardiovascular disease by reducing both serum phosphate and FGF- 3 levels.

La calcificazione vascolare nel paziente con insufficienza renale cronica / M.G. Cozzolino, E. Missaglia, A. Ortiz, A. Bellasi, T. Adragao, T. Apostolous, G. Vescovo, M.A. Gallieni. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 101:11(2010 Nov), pp. 442-452.

La calcificazione vascolare nel paziente con insufficienza renale cronica

M.G. Cozzolino;E. Missaglia;A. Bellasi;M.A. Gallieni
2010-11

Abstract

Patients affected by chronic kidney disease (CKD) suffer by secondary hyperparathyroidism and hyperphosphatemia. The new KDIGO guidelines identify a new definition in CKDMBD (Mineral Bone Disorder), in which vascular calcification plays a central role. In fact, CKD patients that present vascular calcification have highest risk of cardiovascular morbility and mortality. Recently, it has been elucidated that the control of phosphate is one of the major problems for the nephrology community. Furthermore, new markers, such as FGF- 3, have been identified as inducers of vascular calcification and cardiovascular disease in CKD. Therefore, the use of calcium-free phosphate-bindersmay reduce the risk of cardiovascular disease by reducing both serum phosphate and FGF- 3 levels.
Calcium; Cardiovascular risk; Chronic kidney disease; Fibroblast growth factor-23; Hyperparathyroidism; Hyperphosphatemia; Parathyroid hormone; Sevelamer; Vascular calcification
Settore MED/14 - Nefrologia
RECENTI PROGRESSI IN MEDICINA
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/152361
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact